Beersma Matthias F C, Dirven Kristien, van Dam Alje P, Templeton Kate E, Claas Eric C J, Goossens Herman
Department of Medical Microbiology, Center of Infectious Diseases, Leiden University Medical Center, P.O. Box 9600, 2300 RC Leiden, The Netherlands.
J Clin Microbiol. 2005 May;43(5):2277-85. doi: 10.1128/JCM.43.5.2277-2285.2005.
Serology and nucleic acid amplification are the main diagnostic tools for the diagnosis of Mycoplasma pneumoniae infection. Since no reference standard is generally accepted, serologic assays for M. pneumoniae have not been evaluated on a broad scale. In this study, 12 commercially available serologic assays (for immunoglobulin G [IgG] and IgM) and the complement fixation test (CFT) were evaluated by using M. pneumoniae DNA detection by real-time PCR as the "gold standard." The assays tested were Platelia EIA (Bio-Rad), SeroMP EIA (Savyon), Serion classic EIA (Virion/Serion), Biotest EIA (Biotest), Ridascreen EIA (r-Biopharm), AniLabsystems EIA (Labsystems), Novum EIA (Novum Diagnostica), Diagnosys EIA (MP products), Genzyme/Virotech EIA, ImmunoWell EIA (Genbio), ImmunoCard EIA (Meridian), and SerodiaMycoII microparticle agglutination (Fujirebio). Serum samples (n = 46) from 27 PCR-positive patients with a known first day of disease and sera (n = 33) from PCR-negative controls were obtained from prospective studies of acute lower respiratory tract infections. Additionally, control sera (n = 63) from patients with acute viral or bacterial respiratory infections other than those caused by M. pneumoniae were tested. The results showed low specificities for both the Novum and the ImmunoCard IgM assays. The IgM assays with the best performances in terms of sensitivity and specificity were AniLabsystems (77% and 92%, respectively), SeroMP (71% and 88%, respectively), and CFT (65% and 97%, respectively). Good receiver operating characteristic areas under the curve were found for CFT (0.94), the Platelia assay (0.87), and the AniLabsystems assay (0.85). We conclude that there are few commercial serologic assays for the detection of M. pneumoniae infections with appropriate performances in terms of sensitivity and specificity and that PCR has become increasingly important for the diagnosis of M. pneumoniae infections in defined groups of patients.
血清学检测和核酸扩增是诊断肺炎支原体感染的主要诊断工具。由于目前尚无普遍认可的参考标准,因此尚未对肺炎支原体的血清学检测方法进行大规模评估。在本研究中,以实时荧光定量PCR检测肺炎支原体DNA作为“金标准”,对12种市售血清学检测方法(检测免疫球蛋白G[IgG]和IgM)及补体结合试验(CFT)进行了评估。所检测的方法包括普乐可复酶联免疫吸附测定(Bio-Rad公司)、SeroMP酶联免疫吸附测定(Savyon公司)、Serion经典酶联免疫吸附测定(Virion/Serion公司)、Biotest酶联免疫吸附测定(Biotest公司)、Ridascreen酶联免疫吸附测定(r-Biopharm公司)、AniLabsystems酶联免疫吸附测定(Labsystems公司)、Novum酶联免疫吸附测定(Novum Diagnostica公司)、Diagnosys酶联免疫吸附测定(MP产品公司)、Genzyme/Virotech酶联免疫吸附测定、ImmunoWell酶联免疫吸附测定(Genbio公司)、ImmunoCard酶联免疫吸附测定(Meridian公司)以及SerodiaMycoII微粒凝集试验(富士瑞必欧公司)。从急性下呼吸道感染的前瞻性研究中获取了27例PCR检测呈阳性且已知发病首日的患者的血清样本(n = 46)以及PCR检测呈阴性的对照组血清样本(n = 33)。此外,还检测了63例由肺炎支原体以外的急性病毒或细菌呼吸道感染患者的对照血清。结果显示,Novum和ImmunoCard IgM检测方法的特异性较低。在敏感性和特异性方面表现最佳的IgM检测方法分别为AniLabsystems(分别为77%和92%)、SeroMP(分别为71%和88%)以及CFT(分别为65%和97%)。CFT(0.94)、普乐可复检测法(0.87)和AniLabsystems检测法(0.85)的曲线下面积具有良好的诊断效能。我们得出结论,在检测肺炎支原体感染方面,具备适当敏感性和特异性的市售血清学检测方法较少,并且PCR在特定患者群体的肺炎支原体感染诊断中变得越来越重要。